Growth Metrics

Glaukos (GKOS) Preferred Stock Liabilities (2013 - 2014)

Glaukos (GKOS) reported Preferred Stock Liabilities of $157.4 million for Q4 2014, up 0.75% year-over-year from $156.2 million in Q4 2013, and up 0.75% on a QoQ basis from $156.2 million in Q4 2013.

Glaukos (GKOS) has 2 years of Preferred Stock Liabilities data on file, last reported at $157.4 million in Q4 2014.

  • Quarterly Preferred Stock Liabilities rose 0.75% year-over-year to $157.4 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $157.4 million (up 0.75% YoY) and the FY2014 annual result came in at $157.4 million, up 0.75% from the prior year.
  • Preferred Stock Liabilities grew to $157.4 million in Q4 2014 per GKOS's latest filing, from $156.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $157.4 million in Q4 2014 and bottomed at $156.2 million in Q4 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Glaukos 6.00 Bn 5.90 Bn 117.23 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2014 157.38 Mn
Dec 31, 2013 156.21 Mn